This website is intended for healthcare professionals only and contains promotional content.

Report an adverse event here
Link Logo
United Kingdom - English

United Kingdom - English

United Kingdom | English

These country specific websites are specifically intended for healthcare professionals in listed countries only.

Europe

Deutschland - DeutschDeutschland - Deutsch España - EspañolEspaña - Español Italia - ItalianoItalia - Italiano United Kingdom - EnglishUnited Kingdom - English

NOTICE: Kyowa Kirin International has agreed a joint venture with Grünenthal GmbH for the Established Medicines portfolio. The new company, KKI NewCo (known as Grünenthal Meds), is responsible for the content on this page. For more information please click here.​

rectogesic-product-image
rectogesic-caf-relief
rectogesic-introduction

RECTOGESIC®

EFFICACY

RECTOGESIC 4 mg/g Rectal Ointment is indicated in adults for relief of pain associated with chronic anal fissure.

Click here for prescribing information and adverse event reporting.

Efficacy

RECTOGESIC is the only licensed treatment to relieve pain of chronic anal fissure (CAF),1,2 providing effective pain relief within days, sustained over 8 week treatment period as fissure heals.3

Related content

MEDICAL RESOURCES

Explore management and treatment pathways for patients presenting symptoms of chronic anal fissure.

LEARN MORE

MEDICAL EDUCATION

Key guidelines for the diagnosis and management of chronic anal fissure.

LEARN MORE

DISEASE PAGES

How to identify and diagnose chronic anal fissure.

LEARN MORE

Average:

  • References

    1. RECTOGESIC® (glyceryl trinitrate) Summary of Product Characteristics

    2. British National Formulary Online. Available at: https://bnf.nice.org.uk/treatment-summary/anal-fissure.html Last accessed: March 2024.

    3. Bailey HR, Beck DE, Billingham RP, et al. A study to determine the nitroglycerin dose and dosing interval that best promote the healing of chronic anal fissures. Dis. Colon Rectum. 2002;45(9):1192-1199.

    M-RCG-UK-11-23-0004 March 2024